APELLIS PHARMACEUTICALS INC's ticker is APLS and the CUSIP is 03753U106. A total of 149 filers reported holding APELLIS PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 0.48 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $230,149 | -49.1% | 6,051 | +21.8% | 0.00% | -100.0% |
| Q2 2023 | $452,409 | -51.8% | 4,969 | -65.1% | 0.00% | -50.0% |
| Q1 2023 | $938,847 | +463.5% | 14,237 | +338.2% | 0.00% | – |
| Q4 2022 | $166,603 | -20.3% | 3,249 | +6.9% | 0.00% | – |
| Q3 2022 | $209,000 | +74.2% | 3,040 | +14.0% | 0.00% | – |
| Q2 2022 | $120,000 | -9.1% | 2,667 | +2.4% | 0.00% | – |
| Q1 2022 | $132,000 | -16.5% | 2,605 | -22.1% | 0.00% | – |
| Q4 2021 | $158,000 | +19.7% | 3,346 | -16.4% | 0.00% | – |
| Q3 2021 | $132,000 | -5.0% | 4,001 | +80.8% | 0.00% | – |
| Q2 2021 | $139,000 | +46.3% | 2,213 | +0.3% | 0.00% | – |
| Q1 2021 | $95,000 | -27.5% | 2,206 | -3.9% | 0.00% | – |
| Q4 2020 | $131,000 | +79.5% | 2,296 | -4.2% | 0.00% | – |
| Q3 2020 | $73,000 | -6.4% | 2,396 | 0.0% | 0.00% | – |
| Q2 2020 | $78,000 | +14.7% | 2,396 | -6.3% | 0.00% | – |
| Q1 2020 | $68,000 | – | 2,556 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 1,526,122 | $29,759,000 | 24.10% |
| Cormorant Asset Management, LP | 3,600,000 | $70,200,000 | 4.74% |
| SECTORAL ASSET MANAGEMENT INC | 1,727,829 | $33,693,000 | 4.05% |
| Hillhouse Capital Management | 2,098,581 | $40,922,000 | 1.71% |
| HHLR ADVISORS, LTD. | 2,579,708 | $50,304,000 | 1.40% |
| CLOUGH CAPITAL PARTNERS L P | 589,734 | $11,500,000 | 1.01% |
| Vivo Capital, LLC | 383,538 | $7,479,000 | 0.75% |
| Opaleye Management Inc. | 115,000 | $2,243,000 | 0.62% |
| Virtus ETF Advisers LLC | 14,338 | $280,000 | 0.60% |
| Eversept Partners, LP | 104,349 | $2,034,806 | 0.59% |